Skip to Content

Targretin (bexarotene) Disease Interactions

There are 7 disease interactions with Targretin (bexarotene):

Moderate

Bexarotene (Includes Targretin) ↔ Cataracts

Moderate Potential Hazard, Moderate plausibility

Applies to: Cataracts

The use of bexarotene may cause new cataracts or worsening of previous cataracts. It is recommended to monitor closely for the development of any visual difficulties and to have an appropriate ophthalmologic evaluation. Exercise caution when using this agent in patients with a history of cataracts.

Moderate

Bexarotene (Includes Targretin) ↔ Diabetes

Moderate Potential Hazard, Moderate plausibility

Applies to: Diabetes Mellitus

The use of bexarotene may cause hypoglycemia in diabetic patients. It is recommended to measure baseline blood glucose levels and to keep monitoring them closely during treatment. Exercise caution when using this agent in diabetic patients.

Moderate

Bexarotene (Includes Targretin) ↔ Hyperlipidemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyperlipidemia

The use of bexarotene may cause elevations in lipids. It is recommended to monitor lipid levels closely and to obtain a fasting blood lipid reading at baseline and weekly until lipid response to the drug is established. Exercise caution when using this agent in patients with hyperlipidemia.

Moderate

Bexarotene (Includes Targretin) ↔ Hypothyroidism

Moderate Potential Hazard, Moderate plausibility

Applies to: Hypothyroidism

The use of bexarotene may cause hypothyroidism. It is recommended to consider thyroid hormone supplementation in patients with hypothyroidism, to obtain baseline thyroid function tests, and to closely monitor patients during treatment.

Moderate

Bexarotene (Includes Targretin) ↔ Liver Dysfunction

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

In vitro studies suggest that cytochrome P450 3A4 is the major cytochrome P450 responsible for formation of the oxidative metabolites and that the oxidative metabolites may be glucuronidated. It is recommended to monitor for signs of toxicity due to increased drug exposure if bexarotene is used in patients with hepatic impairment as these patients are expected to have a decreased drug clearance.

Moderate

Bexarotene (Includes Targretin) ↔ Neutropenia

Moderate Potential Hazard, Moderate plausibility

Applies to: Neutropenia

The use of bexarotene causes neutropenia. Neutropenia is reversible after dose reduction or discontinuation of treatment. Care should be exercised in patients at risk. It is recommended to obtain complete blood counts at baseline and periodically during treatment.

Moderate

Bexarotene (Includes Targretin) ↔ Pancreatitis

Moderate Potential Hazard, Moderate plausibility

Applies to: Pancreatitis

Pancreatitis, including a fatal case, has occurred in patients receiving bexarotene. It is recommended to monitor for pancreatitis and to interrupt treatment if pancreatitis is suspected. Close monitoring is recommended in patients who have risk factors for pancreatitis, such as high alcohol consumption, uncontrolled diabetes or hyperlipidemia, and prior pancreatitis, as these patients might be at greater risk.

Targretin (bexarotene) drug Interactions

There are 641 drug interactions with Targretin (bexarotene)

Targretin (bexarotene) alcohol/food Interactions

There are 2 alcohol/food interactions with Targretin (bexarotene)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide